在肺血管再生中NTRK2的异形特异性作用
Cheng Tan1,2,3, Ziyi Liu1,2,3, Xiangdi Mao4
1Perinatal Institute, Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
bioRxiv : the preprint server for biology
|June 4, 2025
概括
支气管肺功能障碍症 (BPD) 涉及早产婴儿的肺部发育受损. 一项研究发现,改变神经营养受体铁酶2 (NTRK2) 异型平衡可以恢复肺血管再生,为BPD提供潜在的治疗方法.
科学领域:
- 肺部医学 肺部医学
- 血管生物学 血管生物学
- 发展生物学 发展生物学
背景情况:
- 支气管肺功能障碍症 (BPD) 是早产婴儿的慢性肺部疾病,其特征是肺膜生殖和毛细血管形成受损.
- 内皮功能障碍是BPD病变的关键驱动因素,但其潜在的分子机制尚未完全理解.
研究的目的:
- 研究BPD内皮质功能障碍的分子机制.
- 确定促进BPD血管再生的潜在治疗点.
主要方法:
- 从对照和BPD患者的肺部进行血管内皮细胞的多分子剖析.
- 对神经营养受体氨酸激酶2 (NTRK2) 异型表达和功能的分析.
- 在体内和体外研究使用血管有机体和类似BPD的小鼠模型.
主要成果:
- 在BPD肺部观察到具有异常NTRK2表达的一般毛细体内皮细胞 (gCap) 的扩张.
- 从全长NTRK2 (NTRK2-FL) 病态切换到截断的异型 (NTRK2-T1) 损害了Chap的再生能力.
- 在临床前模型中,通过mRNA疗法恢复NTRK2-FL促进了血管生成,并逆转了气膜简化.
结论:
- NTRK2异型失衡是BPD内皮质功能障碍的关键驱动因素.
- 针对NTRK2的异形特异性RNA疗法为BPD血管修复提供了一个有希望的策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Pulmonary Hypertension: Classification and Pathogenesis
300
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
300
Transducer Mechanism: Enzyme-Linked Receptors
2.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.9K
Enzyme-linked Receptors
80.1K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
80.1K
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.2K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263


